These results strongly suggested that SRPK1 promotes EGFR-TKI resistance in NSCLC by escaping apoptosis during the initial treatment and subsequently, increasing receptor levels to accelerate progression. The gene discussed is SRPK1; the disease is non-small cell lung carcinoma.